Oncolys BioPharma, Inc. (JP:4588)
:4588
Want to see JP:4588 full AI Analyst Report?
4588 Stock Chart & Stats
¥953.00
-¥1.00(-0.20%)
At close: 4:00 PM EST
¥953.00
-¥1.00(-0.20%)
Day’s Range― - ―
52-Week Range¥570.00 - ¥3,695.00
Previous CloseN/A
Volume332.10K
Average Volume (3M)1.52M
Market Cap
¥79.70B
Enterprise Value¥66.00B
Total Cash (Recent Filing)¥1.39B
Total Debt (Recent Filing)¥366.79M
Price to Earnings (P/E)―
Beta2.11
Next Earnings
Jul 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-93.11
Shares Outstanding29,306,700
10 Day Avg. Volume2,742,450
30 Day Avg. Volume1,517,566
Financial Highlights & Ratios
PEG Ratio-4.72
Price to Book (P/B)8.90
Price to Sales (P/S)1247.26
P/FCF Ratio-18.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance-sheet ResilienceOncolys shows a materially strengthened balance sheet with equity and assets rising meaningfully and low leverage. That provides durable capacity to fund clinical programs, absorb near-term losses, and negotiate partnerships without immediate insolvency risk, supporting multi‑month program continuity.
Partnering-driven Revenue ModelThe company's business model centers on milestone, licensing and collaboration revenue rather than large-scale commercial execution. Structurally this reduces the need for costly global commercialization infrastructure and allows risk transfer to partners, offering scalable funding levers as programs advance.
High Gross Margin ProfileReported gross profit near 100% suggests very low direct cost of revenue for current activities, implying favorable unit economics if clinical assets commercialize or are licensed. High gross margins create durable upside for profitability once operating expenses are contained or offset by partner income.
Bears Say
Persistent Cash BurnConsistent, large negative operating and free cash flows mean the business cannot self-fund R&D and operations. Over a 2–6 month horizon this necessitates external financing or material partner milestones; funding risk raises dilution and can force program delays or cuts if new capital or deals are not secured.
Multi-year Revenue CollapseA rapid, sustained drop in revenue erodes the company's ability to cover fixed R&D and SG&A costs and suggests loss or non‑recurrence of prior collaboration income. Structurally, this raises execution risk, reduces bargaining power with partners, and lengthens the timeline to reach a self‑sustaining business model.
Chronic Operating Losses And Negative ROESustained operating losses have produced negative returns on equity over multiple years, progressively eroding shareholder value and limiting internal capital generation. This structural profitability gap requires recurring external funding and constrains strategic optionality over the medium term.
Oncolys BioPharma, Inc. News
4588 FAQ
What was Oncolys BioPharma, Inc.’s price range in the past 12 months?
Oncolys BioPharma, Inc. lowest stock price was ¥570.00 and its highest was ¥3695.00 in the past 12 months.
What is Oncolys BioPharma, Inc.’s market cap?
Oncolys BioPharma, Inc.’s market cap is ¥79.70B.
When is Oncolys BioPharma, Inc.’s upcoming earnings report date?
Oncolys BioPharma, Inc.’s upcoming earnings report date is Jul 31, 2026 which is in 51 days.
How were Oncolys BioPharma, Inc.’s earnings last quarter?
Oncolys BioPharma, Inc. released its earnings results on May 08, 2026. The company reported -¥14.16 earnings per share for the quarter, missing the consensus estimate of N/A by -¥14.16.
Is Oncolys BioPharma, Inc. overvalued?
According to Wall Street analysts Oncolys BioPharma, Inc.’s price is currently Overvalued.
Does Oncolys BioPharma, Inc. pay dividends?
Oncolys BioPharma, Inc. does not currently pay dividends.
What is Oncolys BioPharma, Inc.’s EPS estimate?
Oncolys BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncolys BioPharma, Inc. have?
Oncolys BioPharma, Inc. has 29,306,700 shares outstanding.
What happened to Oncolys BioPharma, Inc.’s price movement after its last earnings report?
Oncolys BioPharma, Inc. reported an EPS of -¥14.16 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.819%.
Which hedge fund is a major shareholder of Oncolys BioPharma, Inc.?
Currently, no hedge funds are holding shares in JP:4588
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncolys BioPharma, Inc.
Oncolys BioPharma Inc. is a biotechnology firm dedicated to the research, development, manufacturing, sales, and distribution of oncolytic viruses, pharmaceutical drugs, and diagnostic agents for tumors across Japan, other Asian regions, and the United States. Its robust pipeline features Telomelysin (OBP-301), an oncolytic adenovirus, currently in Phase II clinical trials for the treatment of gastric, gastroesophageal junction, head and neck, and esophageal cancers, and in Phase I trials for hepatocellular carcinoma. Other key developments include OBP-702, a telomerase-specific oncolytic adenovirus in preclinical stages for solid tumors; OBP-2011, also preclinical, targeting SARS-CoV-2 infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed Phase IIb clinical trials for HIV; and OBP-801, a histone deacetylase inhibitor, which is in Phase I clinical trials for solid tumors and preclinical assessment for ophthalmic applications. Additionally, the company is advancing TelomeScan (OBP-401 and OBP-1101), a cancer detection drug designed to identify living circulating tumor cells in cancer patients' blood. Oncolys BioPharma also offers diagnostic medications and inspection services. The company boasts various licensing and collaborative agreements with institutions such as Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc. Founded in 2004, Oncolys BioPharma Inc. is based in Tokyo, Japan.
Technical Analysis
Peptidream
―
OncoTherapy Science
―
CanBas Co., Ltd.
―
Chiome Bioscience Inc.
―
Takara Bio Inc.
―
Options Prices
Currently, No data available
---